{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:11:40Z","timestamp":1748405500901,"version":"3.41.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"DOI":"10.7759\/cureus.84881","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:11:54Z","timestamp":1748340714000},"source":"Crossref","is-referenced-by-count":0,"title":["Patients\u2019 Preferences and the Time to Finish Gonadotropin-Releasing Hormone (GnRH) Agonist and Antagonist Injections in Japanese Prostate Cancer Patients"],"prefix":"10.7759","author":[{"given":"Takashi","family":"Kawahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Hasizume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Teranishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"168","author":"Huggins C","year":"2002","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 2002, 168:9-12. 10.1016\/s0022-5347(05)64820-3","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1987.tb04842.x","article-title":"The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630","volume":"59","author":"Beacock CJ","year":"1987","unstructured":"Beacock CJ, Buck AC, Zwinck R, et al.. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630. Br J Urol. 1987, 59:436-42. 10.1111\/j.1464-410x.1987.tb04842.x","journal-title":"Br J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2012.01.092","article-title":"The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients","volume":"80","author":"Damber JE","year":"2012","unstructured":"Damber JE, Tammela TL, Iversen P, et al.. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology. 2012, 80:174-80. 10.1016\/j.urology.2012.01.092","journal-title":"Urology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz L","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, et al.. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008, 102:1531-8. 10.1111\/j.1464-410X.2008.08183.x","journal-title":"BJU Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13600","article-title":"Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: a phase III study","volume":"109","author":"Ozono S","year":"2018","unstructured":"Ozono S, Tsukamoto T, Naito S, et al.. Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: a phase III study. Cancer Sci. 2018, 109:1920-9. 10.1111\/cas.13600","journal-title":"Cancer Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.25.23294461","article-title":"Patients\u2019 preference and time to finish injection for GnRH agonist and GnRH antagonist in Japanese prostate cancer patients. [PREPRINT]","author":"Kawahara T","year":"2023","unstructured":"Kawahara T, Uemura H. Patients\u2019 preference and time to finish injection for GnRH agonist and GnRH antagonist in Japanese prostate cancer patients. [PREPRINT]. mediRxiv. 2023, 10.1101\/2023.08.25.23294461","journal-title":"mediRxiv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65549","article-title":"An age-specific crisis awareness survey of COVID-19 vaccines and treatments among healthy Japanese adults","volume":"16","author":"Kawahara T","year":"2024","unstructured":"Kawahara T, Takeshima T, Makiyama K, Uemura H. An age-specific crisis awareness survey of COVID-19 vaccines and treatments among healthy Japanese adults. Cureus. 2024, 16:e65549. 10.7759\/cureus.65549","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00028.x","article-title":"Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer","volume":"83","author":"Sarosdy MF","year":"1999","unstructured":"Sarosdy MF, Schellhammer PF, Soloway MS, et al.. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int. 1999, 83:801-6. 10.1046\/j.1464-410x.1999.00028.x","journal-title":"BJU Int"},{"key":"ref9","article-title":"Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis","volume":"21","author":"Nyg\u00e5rd R","year":"2001","unstructured":"Nyg\u00e5rd R, Norum J, Due J. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res. 2001, 21:781-8.","journal-title":"Anticancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16311","article-title":"Comparison of quality of life and injection site reactions after switching from degarelix 80 mg to 480 mg in advanced prostate cancer: a prospective trial","volume":"43","author":"Miyajima K","year":"2023","unstructured":"Miyajima K, Yanagisawa T, Suzuki H, et al.. Comparison of quality of life and injection site reactions after switching from degarelix 80 mg to 480 mg in advanced prostate cancer: a prospective trial. Anticancer Res. 2023, 43:1611-21. 10.21873\/anticanres.16311","journal-title":"Anticancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000353917","article-title":"Fifteen-second skin icing using a frozen gel pack is effective for reducing goserelin injection pain","volume":"93","author":"Naya Y","year":"2014","unstructured":"Naya Y, Hagiwara N, Takeuchi I, Mori M, Inagaki A, Nakanouchi T, Mikami K. Fifteen-second skin icing using a frozen gel pack is effective for reducing goserelin injection pain. Urol Int. 2014, 93:202-6. 10.1159\/000353917","journal-title":"Urol Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500778","article-title":"Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection","volume":"8","author":"Montgomery BS","year":"2005","unstructured":"Montgomery BS, Borwell JP, Higgins DM. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection. Prostate Cancer Prostatic Dis. 2005, 8:66-8. 10.1038\/sj.pcan.4500778","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365929-patients-preferences-and-the-time-to-finish-gonadotropin-releasing-hormone-gnrh-agonist-and-antagonist-injections-in-japanese-prostate-cancer-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:11:55Z","timestamp":1748340715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365929-patients-preferences-and-the-time-to-finish-gonadotropin-releasing-hormone-gnrh-agonist-and-antagonist-injections-in-japanese-prostate-cancer-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.84881","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}